Roche boosts respiratory drug pipeline with $8.3B InterMune buy | ViiV's HIV combination drug Triumeq gains FDA approval | Lilly to seek regulatory approval of psoriasis drug after trial success
Web Version
August 25, 2014
Bio SmartBrief

Today's Top Story
Roche boosts respiratory drug pipeline with $8.3B InterMune buy
Roche Holding agreed to pay $8.3 billion in cash to acquire California-based biotech firm InterMune and its promising new drug pirfenidone, which is under regulatory review in the U.S. and already approved in Europe and Canada for the treatment of idiopathic pulmonary fibrosis. The deal would enable the Swiss drugmaker to boost its respiratory drug pipeline, Roche CEO Severin Schwan said. Reuters (8/24), The Wall Street Journal (tiered subscription model) (8/24)
Share: LinkedInTwitterFacebookGoogle+Email
Health Care & Policy
ViiV's HIV combination drug Triumeq gains FDA approval
ViiV Healthcare has received the FDA's approval to market its once-daily pill Triumeq, a fixed-dose combination of antiviral drugs dolutegravir, abacavir, and lamivudine for treating HIV patients 18 and older. The approval makes Triumeq the second HIV single-dose regimen containing an integrase inhibitor to win FDA clearance, after Gilead's Stribild. Bloomberg (8/22), Medscape (free registration) (8/22)
Share: LinkedInTwitterFacebookGoogle+Email
Lilly to seek regulatory approval of psoriasis drug after trial success
Eli Lilly and Co. plans to submit its experimental psoriasis drug ixekizumab for regulatory review next year after obtaining positive results in three late-stage trials. Data from the trials showed that ixekizumab was more effective than Pfizer's Enbrel, or etanercept, on all skin-clearance measures. Between 78% and 90% of participants treated with ixekizumab also had a psoriasis area and severity index score reduction of at least 75%, while 31% to 41% achieved clear skin after 12 weeks of treatment. PharmaTimes (U.K.) (8/21)
Share: LinkedInTwitterFacebookGoogle+Email
Baxter's long-acting drug hits primary goal in hemophilia A trial
Baxter International has announced that BAX 855, an investigational long-acting treatment for hemophilia A, met the primary endpoint in a Phase III study. Preventive use of the drug was associated with greater reductions in bleeding rates than on-demand administration. Reuters (8/21)
Share: LinkedInTwitterFacebookGoogle+Email
J&J signs deal for ViaCyte's diabetes drug candidate
ViaCyte granted Johnson & Johnson "a future right to evaluate a transaction" tied to its experimental stem cell treatment VC-01 for type 1 diabetes. In exchange, ViaCyte received a $20 million payment. ViaCyte said it intends to soon initiate a Phase I/II study of the drug following the FDA's acceptance of its investigational new drug application last week. PharmaTimes (U.K.) (8/21)
Share: LinkedInTwitterFacebookGoogle+Email
EMD signs supply deal with Samsung BioLogics
EMD Millipore agreed to supply raw materials for Samsung BioLogics' biopharmaceutical manufacturing facilities under a memorandum of understanding. The deal covers Samsung's 30 KL plant and its new 150 KL facility in South Korea that is expected to be finished next year. Genetic Engineering & Biotechnology News (8/22)
Share: LinkedInTwitterFacebookGoogle+Email
Company & Financial News
Up to $12 million offered for evolutionary studies of infectious diseases
The National Institutes of Health, National Science Foundation and the Department of Agriculture, together with the U.K.'s Biotechnology and Biological Sciences Research Council and the U.S.-Israel Binational Science Foundation, will provide up to $12 million to support multidisciplinary genomic research. The projects will focus on how infectious disease pathogens evolve, interact and spread. GenomeWeb Daily News (free registration) (8/21)
Share: LinkedInTwitterFacebookGoogle+Email
Fla. cancer genetic testing firm raises $34.6M from stock sale
Florida-based NeoGenomics, which specializes in cancer genetic screening services, has obtained net proceeds of $34.6 million in its latest public shares offering. The company will use part of the money to support general corporate functions, including debt repayment and possible acquisitions. GenomeWeb Daily News (free registration) (8/22)
Share: LinkedInTwitterFacebookGoogle+Email
The Latest From BIO ...
Announcing the BIO Latin America Conference!
Join high level executives, academics and investors in Rio de Janeiro, September 9-11, to discuss trends, navigate industry challenges, attend company presentations, conduct 1x1 partnering meetings and learn about investment opportunities within this emerging market. Register now.
Share: LinkedInTwitterFacebookGoogle+Email
Food & Agriculture
GeneSeek to provide genomic profiling services to beef cattle breeders
GeneSeek, a unit of Neogen, agreed to provide genomic profiling services to the International Brangus Breeders Association. Under terms of the deal, GeneSeek will help breeders determine cattle percentage using its Genomic Profiler technologies. The deal creates "a foundation for genomic-enhanced [expected progeny differences] for the breed association," the association said. GenomeWeb Daily News (free registration) (8/22)
Share: LinkedInTwitterFacebookGoogle+Email
Hot Topics
Industrial & Environmental
Cellulosic ethanol plant helps Iowa farmer lessen waste
Mike Greenfield, a farmer in Hamilton County, Iowa, is thankful that the DuPont cellulosic ethanol plant in Nevada, Iowa, has given him the opportunity to earn money from the corn residue on his farm. New corn hybrids result in tough residues that make it difficult to clear the field, affecting yield, Greenfield said. DuPont's workers leave enough residue on the ground to maintain the soil's productivity, Greenfield said. Iowa Farmer Today (8/21)
Share: LinkedInTwitterFacebookGoogle+Email
News From BIO
Registration is open for the BIO Investor Forum!
The BIO Investor Forum, October 7-8 in San Francisco, is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One Partnering meetings. Register today to explore investment trends and opportunities in life sciences and connect with key stakeholders in the industry.
Share: LinkedInTwitterFacebookGoogle+Email
Who's Hiring?
Position TitleCompany NameLocation
Manager, Partnering OperationsBIODist. Columbia
Director of Regulatory Affairs, Food and AgricultureBIODist. Columbia
Click here to view more job listings.
Don't be afraid to give up the good to go for the great."
-- John D. Rockefeller,
American industrialist
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about BIO ->Conferences | Join Bio | Media | Issues | Industry
The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Tara Rosenzweig
Advertising:  Meryl Harold
  P: 202.407.7828

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information